In 2026, Huanghai Medicine (00013) announced the Phase III data of the ESLIM-02 study for the treatment of warm antibody type autoimmune hemolytic anemia with Soluximab at the European Hematology Association annual meeting.

Wisdom Financial APP News, and Hutchison Pharmaceuticals (00013) announced that the Phase III results of the ESLIM-02 China study of Soluximab in the treatment of warm autoantibody hemolytic anemia (wAIHA) patients will be presented at the European Hematology Association (EHA) Annual Meeting in Stockholm, Sweden on June 11, 2026 (Thursday).